Galderma Joins SMI After 24.6% H1 Sales Growth
Galderma enters the Swiss Market Index after raising 2026 guidance to 19-21% growth. L'Oréal retains 20% stake.
Key points
- Galderma joins the Swiss Market Index on September 21, 2026.
- First-half 2026 net sales grew 24.6% year-on-year at constant currency.
- Full-year 2026 sales growth guidance was raised to 19-21%.
Galderma begins trading in the Swiss Market Index on September 21. The inclusion marks a rapid ascent since its 2024 listing.
The company posted 24.6% year-on-year sales growth in the first half of 2026. This performance triggered the upgrade to the blue-chip benchmark.
Sales Growth Drives Index Inclusion
Net sales rose from 4.410 billion USD in 2024 to 5.207 billion USD in 2025. The increase stems from expansion across three product categories.
First-half 2026 results exceeded internal projections significantly. The firm raised full-year growth guidance to 19-21% from 17-20%. Core EBITDA margin remains targeted at approximately 26%.
Shareholder Structure Supports Market Position
L'Oréal Group holds 20% of Galderma shares as a major investor. The remaining 80% of shares are in free float for public trading.
This broad shareholder base strengthens Galderma's liquidity and market visibility. It supports the company's status as a leading global dermatology provider.
Strategic Focus on Dermatology Leadership
Galderma operates in approximately 90 countries with a science-based portfolio. The strategy covers injectable aesthetics, skincare, and therapeutic dermatology segments.
Management attributes the SMI entry to disciplined execution and innovation. The company aims to consolidate its position as the world's leading dermatology powerhouse.
